New cell therapy combo takes on deadly brain cancer

NCT ID NCT00807027

Completed Disease control Sponsor: GC Cell Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested whether adding a cell therapy called Immuncell-LC to standard chemotherapy (temozolomide) helps people with newly diagnosed glioblastoma, an aggressive brain cancer. The study enrolled 180 patients in Korea who had surgery for glioblastoma. Researchers measured how long patients lived without the cancer getting worse and overall survival. The goal was to see if the combination is more effective than chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immuncell-LC (activated T lymphocytes) plus temozolomide
What this could lead to: If successful, this combination could improve progression-free survival and overall survival for people with newly diagnosed glioblastoma.
What could go wrong: This is a completed Phase 3 trial, but results are not yet widely confirmed. Glioblastoma is very aggressive, and even positive findings may offer only modest benefit. Risks include side effects from chemotherapy and the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Gyunghee University Medical Center

Seoul, South Korea
Hanyang University Guri Hospital

Guri-si, Gyeonggi-do, South Korea
Konkuk University

Seoul, South Korea
Korea University Anam Hospital

Seoul, South Korea
Samsung Seoul Medical Center

Seoul, South Korea
Seoul Asan Medical Center

Seoul, South Korea
Yeonsei University Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.